Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
NCT00021723
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
375
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL:
AN-1792 also known as AIP-001
Sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Collaborators
[object Object]